Mechanisms of Fate Evolution of Colorectal Adenocarcinoma Metastasis
NCT ID: NCT04714814
Last Updated: 2021-03-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
200 participants
OBSERVATIONAL
2021-06-01
2023-05-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Mechanism and Process Regulation for Colorectal Tumors
NCT04707482
Distinct Metastatic Phenotypes Between Early-onset and Late-onset Colorectal Cancer
NCT06040021
The Role of 18F-FDG and 68Ga-FAPI PET/CT in the Diagnosis and the Efficacy Evaluation of Advanced Colorectal Cancer (peritoneal Metastasis With/without Other Metastases)
NCT06601075
3D Bioprinted Models for Predicting Chemotherapy Response in Colorectal Cancer With/Without Liver Metastases
NCT04755907
Perioperative Chemotherapy Plus Cetuximab Versus Chemotherapy Alone for High Risk Resectable Colorectal Liver Metastasis
NCT03031444
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Physical condition (ECOG) score ≤ 1.
3. Colorectal adenocarcinoma was confirmed by histopathology.
4. No family history of hereditary tumor.
5. Accept standard radical resection of colorectal cancer, R0 resection, number of lymph node dissection ≥ 12.
6. Preoperative clinical stage is stage III.
7. Agree to receive standard fluorouracil ±oxaliplatin adjuvant chemotherapy for 3 to 6 months.
8. Enough primary surgical or biopsy tissues for examination.
9. Enough peripheral blood samples for examination.
10. Agree to sign informed consent to participate in this project.
1. Aged 18-75.
2. Histopathological diagnosed colonic or rectal adenocarcinoma of stage IV.
3. Not yet received antineoplastic therapy.
4. Baseline imaging evaluation shows at least one measurable focus.
5. Sufficient primary surgical or biopsy tissues and metastatic tissues of at least one organ for examination.
6. Enough peripheral blood samples for examination.
7. Expected survival time ≥ 3 months.
8. Provide information such as demography, current medical history or current tumor disease, pathological diagnosis and staging of tumor, physical status of ECOG, radiographic evaluation of tumor, etc.
9. Agree to sign informed consent to participate in this project.
1. Aged 18-75.
2. Physical condition (ECOG) score ≤ 1.
3. Colorectal adenocarcinoma was confirmed by histopathology.
4. No family history of hereditary tumor.
5. Accept standard radical resection of colorectal cancer, R0 resection, number of lymph node dissection ≥ 12.
6. Preoperative clinical stage is stage III and the postoperative pathological stage was confirmed as stage III.
7. Agreed to receive standard fluorouracil ±oxaliplatin adjuvant chemotherapy for 3 to 6 months.
8. Enough primary surgical or biopsy tissues for examination.
9. Enough peripheral blood samples for examination.
10. Agree to sign informed consent to participate in this project.
Exclusion Criteria
2. Postoperative pathological stage was confirmed as stage II.
3. Abnormal function of heart, lung, liver, kidney, hematopoiesis or bone marrow reserve, which cannot tolerate operation or chemotherapy.
4. Diagnosed with malignant tumors that have progressed or need to be treated in the past 5 years, except for cured skin basal cells and skin squamous cell carcinoma.
5. Having mental illness or other serious cardiovascular diseases.
6. Pregnancy or lactation or planned pregnancy within one year.
7. Emergency operation (perforation, bleeding, intestinal obstruction, etc.).
1. Family history of hereditary colorectal cancer, such as Lynch syndrome, familial adenomatous polyposis, P-J syndrome, etc.
2. Nervous system metastasis.
3. Complicated with other malignant tumors.
4. Having poorly controlled chronic concomitant diseases that affect the prognosis.
5. Any complication that may affect the results of the study .
1. Participating in interventional clinical studies or receiving research treatments that influence patients' treatment decisions.
2. Abnormal function of heart, lung, liver, kidney, hematopoiesis and bone marrow reserve, which cannot tolerate operation and chemotherapy.
3. Diagnoses with malignant tumors that have progressed or need to be treated in the past 5 years, except for cured skin basal cells and skin squamous cell carcinoma.
4. Having mental illness or other serious cardiovascular disease.
5. Pregnancy or lactation or planned pregnancy within one year.
6. Emergency operation (perforation, bleeding, intestinal obstruction, etc.).
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Shanghai Municipal Science and Technology Commission
OTHER_GOV
RenJi Hospital
OTHER
Shanghai Jiao Tong University School of Medicine
OTHER
Shanghai Minimally Invasive Surgery Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Sun Jing, PhD
Role: PRINCIPAL_INVESTIGATOR
Shanghai Jiao Tong University School of Medicine
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Shanghai Ruijin Hospttal
Shanghai, Sahgnhai, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Metastatic CRC cell fate
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.